BioNTech, OncoC4’s antibody more than halves risk of death in Phase 3 lung cancer trial

BioNTech and OncoC4 shared positive survival data from a late-stage trial of their drug candidate in lung cancer that was previously hit with a partial hold by the FDA. The biotech’s treatment, called gotistobart, slashed ...